دورية أكاديمية
Effects of Nigella sativa on outcome of hepatitis C in Egypt.
| العنوان: | Effects of Nigella sativa on outcome of hepatitis C in Egypt. |
|---|---|
| المؤلفون: | Barakat EM; Eman Mahmoud Fathy Barakat, Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt., El Wakeel LM, Hagag RS |
| المصدر: | World journal of gastroenterology [World J Gastroenterol] 2013 Apr 28; Vol. 19 (16), pp. 2529-36. |
| نوع المنشور: | Controlled Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing : WJG Press, c1998- |
| مواضيع طبية MeSH: | Nigella sativa*, Antioxidants/*therapeutic use , Antiviral Agents/*therapeutic use , Hepatitis C/*drug therapy , Plant Extracts/*therapeutic use , Plant Oils/*therapeutic use, Adult ; Antioxidants/adverse effects ; Antiviral Agents/adverse effects ; Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Drug Interactions ; Egypt ; Female ; Hepatitis C/blood ; Hepatitis C/diagnosis ; Humans ; Liver Function Tests ; Male ; Middle Aged ; Oxidative Stress/drug effects ; Phytotherapy ; Pilot Projects ; Plant Extracts/adverse effects ; Plant Oils/adverse effects ; Plants, Medicinal ; Prospective Studies ; Time Factors ; Treatment Outcome ; Viral Load |
| مستخلص: | Aim: To evaluate the safety, efficacy and tolerability of Nigella sativa (N. sativa) in patients with hepatitis C not eligible for interferon (IFN)-α. Methods: Thirty patients with hepatitis C virus (HCV) infection, who were not eligible for IFN/ribavirin therapy, were included in the present study. Inclusion criteria included: patients with HCV with or without cirrhosis, who had a contraindication to IFN-α therapy, or had refused or had a financial constraint to IFN-α therapy. Exclusion criteria included: patients on IFN-α therapy, infection with hepatitis B or hepatitis I virus, hepatocellular carcinoma, other malignancies, major severe illness, or treatment non-compliance. Various parameters, including clinical parameters, complete blood count, liver function, renal function, plasma glucose, total antioxidant capacity (TAC), and polymerase chain reaction, were all assessed at baseline and at the end of the study. Clinical assessment included: hepato and/or splenomegaly, jaundice, palmar erythema, flapping tremors, spider naevi, lower-limb edema, and ascites. N. sativa was administered for three successive months at a dose of (450 mg three times daily). Clinical response and incidence of adverse drug reactions were assessed initially, periodically, and at the end of the study. Results: N. sativa administration significantly improved HCV viral load (380808.7 ± 610937 vs 147028.2 ± 475225.6, P = 0.001) and TAC (1.35 ± 0.5 vs 1.612 ± 0.56, P = 0.001). After N. sativa administration, the following laboratory parameters improved: total protein (7.1 ± 0.7 vs 7.5 ± 0.8, P = 0.001), albumin (3.5 ± 0.87 vs 3.69 ± 0.91, P = 0.008), red blood cell count (4.13 ± 0.9 vs 4.3 ± 0.9, P = 0.001), and platelet count (167.7 ± 91.2 vs 198.5 ± 103, P = 0.004). Fasting blood glucose (104.03 ± 43.42 vs 92.1 ± 31.34, P = 0.001) and postprandial blood glucose (143.67 ± 72.56 vs 112.1 ± 42.9, P = 0.001) were significantly decreased in both diabetic and non-diabetic HCV patients. Patients with lower-limb edema decreased significantly from baseline compared with after treatment [16 (53.30%) vs 7 (23.30%), P = 0.004]. Adverse drug reactions were unremarkable except for a few cases of epigastric pain and hypoglycemia that did not affect patient compliance. Conclusion: N. sativa administration in patients with HCV was tolerable, safe, decreased viral load, and improved oxidative stress, clinical condition and glycemic control in diabetic patients. |
| References: | Hepatology. 1999 Feb;29(2):328-33. (PMID: 9918906) Am J Gastroenterol. 2005 Nov;100(11):2447-52. (PMID: 16279899) J Altern Complement Med. 2008 Nov;14(9):1137-44. (PMID: 18991514) Phytother Res. 2003 Apr;17(4):299-305. (PMID: 12722128) Int J Med Sci. 2006;3(2):47-52. (PMID: 16614742) Arch Med Res. 2007 Aug;38(6):652-60. (PMID: 17613357) Am J Gastroenterol. 1996 Jul;91(7):1480-1. (PMID: 8678039) Clin Liver Dis. 2001 Nov;5(4):931-53. (PMID: 11685802) Hepatology. 2000 Feb;31(2):513-20. (PMID: 10655279) J Med Virol. 2009 Jun;81(6):1015-23. (PMID: 19382263) Int Immunopharmacol. 2005 Dec;5(13-14):1749-70. (PMID: 16275613) J Ethnopharmacol. 2000 Apr;70(1):1-7. (PMID: 10720783) Ann Ital Med Int. 2001 Oct-Dec;16(4):256-9. (PMID: 11799634) J Ethnopharmacol. 2003 Sep;88(1):63-8. (PMID: 12902052) N Engl J Med. 1985 Nov 14;313(20):1256-62. (PMID: 4058506) World J Gastroenterol. 2010 Apr 28;16(16):1943-52. (PMID: 20419831) J Clin Gastroenterol. 2001 Mar;32(3):245-7. (PMID: 11246355) Int J Immunopharmacol. 2000 Sep;22(9):707-18. (PMID: 10884591) Indian J Physiol Pharmacol. 2010 Oct-Dec;54(4):344-54. (PMID: 21675032) Free Radic Biol Med. 1997;22(1-2):287-305. (PMID: 8958154) J Hepatol. 1994 Dec;21(6):1135-9. (PMID: 7699240) Hepatology. 2000 Jul;32(1):111-5. (PMID: 10869297) Hepatology. 2005 Jun;41(6):1211-9. (PMID: 15915465) J Hepatol. 2011 Jun;54(6):1250-62. (PMID: 21316497) Drugs. 2001;61(14):2035-63. (PMID: 11735632) J Clin Gastroenterol. 2001 Sep;33(3):232-3. (PMID: 11500615) Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400. (PMID: 9184771) Nahrung. 1998 Oct;42(5):290-4. (PMID: 9882224) J Agric Food Chem. 2003 Nov 19;51(24):6961-9. (PMID: 14611155) World J Gastroenterol. 2008 Sep 7;14(33):5204-9. (PMID: 18777598) J Exp Med. 1988 Dec 1;168(6):2403-8. (PMID: 2974067) Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S97-S101. (PMID: 16234071) Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):399-405. (PMID: 17439407) Microbes Infect. 2010 Apr;12(4):263-71. (PMID: 20080204) Semin Dial. 2004 Nov-Dec;17(6):432-7. (PMID: 15660573) Biol Pharm Bull. 2001 Mar;24(3):307-10. (PMID: 11256491) Carcinogenesis. 1998 Jun;19(6):1053-9. (PMID: 9667744) J Pak Med Assoc. 1991 Aug;41(8):185-7. (PMID: 1942479) Mutat Res. 2008 Jul-Aug;659(1-2):176-84. (PMID: 18346933) Hepatology. 2002 Apr;35(4):947-52. (PMID: 11915043) Virol J. 2010 Dec 31;7:375. (PMID: 21194423) Therapie. 2000 May-Jun;55(3):379-82. (PMID: 10967716) Clin Infect Dis. 2003 Aug 15;37(4):533-41. (PMID: 12905138) J Biol Chem. 2000 Jan 28;275(4):2247-50. (PMID: 10644669) Phytother Res. 2000 Aug;14(5):323-8. (PMID: 10925395) Gastroenterol Clin Biol. 1996;20(6-7):544-8. (PMID: 8881566) Biol Trace Elem Res. 2003 Winter;96(1-3):263-70. (PMID: 14716106) Geriatrics. 1969 Jan;24(1):91-9. (PMID: 5782543) J Clin Epidemiol. 1997 Jun;50(6):693-703. (PMID: 9250267) J Clin Epidemiol. 1996 May;49(5):519-26. (PMID: 8636725) World J Gastroenterol. 2005 Mar 7;11(9):1356-60. (PMID: 15761975) Int J Diabetes Dev Ctries. 2008 Jan;28(1):11-4. (PMID: 19902033) J Hepatol. 2011 Aug;55(2):245-64. (PMID: 21371579) Lancet. 2000 May 13;355(9216):1707-12. (PMID: 10905258) Isr J Med Sci. 1996 Jul;32(7):526-30. (PMID: 8756978) |
| فهرسة مساهمة: | Keywords: Hepatitis C virus; Nigella sativa; Oxidative stress; Viral load |
| المشرفين على المادة: | 0 (Antioxidants) 0 (Antiviral Agents) 0 (Biomarkers) 0 (Blood Glucose) 0 (Plant Extracts) 0 (Plant Oils) C2J9B08Q3I (caraway oil) |
| تواريخ الأحداث: | Date Created: 20130516 Date Completed: 20131231 Latest Revision: 20220318 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3646144 |
| DOI: | 10.3748/wjg.v19.i16.2529 |
| PMID: | 23674855 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2219-2840 |
|---|---|
| DOI: | 10.3748/wjg.v19.i16.2529 |